Literature DB >> 32097904

Hyponatremia in Oncology Patients.

Christian Grohé.   

Abstract

Hyponatremia is frequent in cancer patients and potentially deleterious. Cancer patients have specific requirements due to the nature and treatment of their disease, which can directly impact the occurrence and severity of hyponatremia, and limit treatment choices. Although essential for successful hyponatremia management, appropriate diagnostic testing is not routinely performed in the current practice. Despite clear evidence that hyponatremia is associated with poor outcome in oncology patients, most patients are still hyponatremic while under observation. Guidance on specific treatment of cancer patients with hyponatremia is needed to optimize patient care in the face of these challenges.
© 2019 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2019        PMID: 32097904     DOI: 10.1159/000493245

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  1 in total

1.  The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells.

Authors:  G Marroncini; C Anceschi; L Naldi; B Fibbi; F Baldanzi; M Maggi; A Peri
Journal:  J Endocrinol Invest       Date:  2022-05-23       Impact factor: 5.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.